Breaking News

Galapagos Discovers New Class of Antibiotics

November 26, 2012

CAM-1 shows strong activity against drug-resistant MRSA

Galapagos NV has discovered a new class of antibiotics and has selected a candidate drug, CAM-1, that shows strong activity against all tested drug resistant Staphylococcus aureus, including hospital and community acquired MRSA strains. MRSA is a potentially life-threatening infection that occurs most frequently among patients in hospitals.
 
This antibiotic works by inhibiting the target DNA pol III alpha, an enzyme present in all bacteria and essential for their growth; this target is absent in humans. CAM-1 was tested against more than 250 different bacterial strains and effectively killed 100% of all drug resistant Staph. aureus, including MRSA, according to the company. Galapagos plans to initiate trials in the first quarter 2014.
 
"Selection of a candidate antibiotic in our MRSA development program is an important step toward realizing the full potential of our unique anti- bacterial program," said Dr. Piet Wigerinck, chief scientific officer of Galapagos. "Our antibiotics have a novel mode of action which brings all tested MRSA strains to a complete halt. Combined with a diagnostic test, these compounds could bring a real solution to MRSA infections."

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems